Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

Background Inhaled short-acting β2-agonists (SABA) is recognised as an effective treatment in adults and older children with asthma, but the effect in young children and infants is still up for debate ...

Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs) added to long-acting β 2-agonists (LABAs) for treatment of symptomatic patients with severe and very severe COPD.

Background: Some studies have suggested that use of long-acting β 2-agonists (LABAs) leads to an increased risk for adverse events in patients with stable COPD. The purpose of this review was to ...

DD01 is a long-acting dual agonist of glucagon-like peptide-1 (GLP ... and safety of DD01 in obese/overweight patients with type 2 diabetes and metabolic dysfunction-associated fatty liver disease.

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson’s ...

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson's ...

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson’s disease ...

According to the newly published case-control study among people diagnosed with asthma or COPD, the use of inhaled short- or long-acting beta-2 agonists at least three years before Parkinson's ...